Grail, Inc.
A healthcare company that makes the Galleri test, a single blood draw that can screen for dozens of types of cancer at once by spotting DNA fragments shed by tumors. The company was born in 2016 when DNA-sequencing firm Illumina spun it out after researchers noticed, while testing pregnant women, that tumor DNA could be found in a routine blood sample. Its name comes from the "holy grail" of medicine—a simple, non-invasive test that catches cancer early.
Bought 78.8K · Sold 339.8K
Sold 1.00M
Granted 959.9K · Sold 442.8K
Granted 744.1K · Sold 349.9K
Granted 442.3K · Sold 183.7K
Sold 1.5K
Granted 45.2K
Granted 42.7K
Granted 42.6K
Granted 42.6K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Ding Chun R10% owner · 8 transactions | — | 10.47Mas of Jul 2025 | — | 78.8K | 339.8K |
| Illumina, Inc.10% owner · 2 transactions | — | 3.50M | — | — | 1.00M |
| Ragusa Robert PChief Executive Officer, Director · 19 transactions | — | 518.6K | 959.9K | — | 442.8K |
| Ofman Joshua J.Chief Executive Officer, Director · 25 transactions | — | 402.3K | 744.1K | — | 349.9K |
| Freidin AaronChief Financial Officer · 20 transactions | — | 260.7K | 442.3K | — | 183.7K |
| Partridge Andrew JohnChief Growth Officer · 1 transaction | — | 163.7K | — | — | 1.5K |
| Summe Gregory LDirector · 11 transactions | — | 45.2K | 45.2K | — | — |
| Chase William JDirector · 11 transactions | — | 42.7K | 42.7K | — | — |
| Krevans SarahDirector · 3 transactions | — | 42.6K | 42.6K | — | — |
| Mizell StevenDirector · 11 transactions | — | 42.6K | 42.6K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 5 years: -2.24M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.